Scientists Advance Understanding of Psychedelic Mechanisms Through New Research Tools and Theories

Scientists are advancing psychedelic medicine through innovative tools and theories. Researchers have introduced the "apical hypercontextualisation" theory, explaining how psychedelics shift cortical processing toward relational context. Concurrently, scientists engineered VCU-1012, a novel quipazine analog that selectively targets the serotonin 2A receptor to promote brain plasticity and alleviate depression-like symptoms in mice while successfully avoiding off-target gut receptors that cause nausea.

HTR2A receptor mapping tools

• ▪The Htr2a reporter mouse lines incorporate a bicistronic design with either Cre or CreERT2 to facilitate genetic labeling of cells expressing the 5-hydroxytryptamine 2A receptor.
• ▪Two of the engineered Htr2a reporter mouse lines feature enhanced green fluorescent protein fusion proteins, with one containing a humanized mouse receptor and the other containing the native mouse receptor.
• ▪Researchers developed three Htr2a reporter mouse lines using CRISPR-mediated recombination at the endogenous Htr2a locus to facilitate the identification and targeting of the 5-hydroxytryptamine 2A receptor in vivo.

Apical hypercontextualisation theory

• ▪Under the apical hypercontextualisation model, basal dendrites process local, feature-specific inputs, while apical dendrites gather remote, contextual signals and expectations from distant cortical regions and the thalamus.
• ▪The "apical hypercontextualisation" framework, published in Neuroscience & Biobehavioral Reviews, proposes a bottom-up neurobiological mechanism explaining how psychedelics alter perception and cognition through layer V cortical pyramidal neurons.
• ▪Serotonin 2A receptor agonism by psychedelics skews layer V pyramidal neuron output toward the apical compartment, causing cells to fire based on relationships and context rather than raw sensory inputs.

VCU-1012 selective psychedelic development

• ▪Researchers synthesized VCU-1012, a modified version of the psychedelic compound quipazine, designed to selectively target the serotonin 2A receptor while avoiding receptors that trigger gastrointestinal side effects.
• ▪In laboratory tests, mice treated with a single dose of VCU-1012 exhibited less passive coping behavior one day after treatment, indicating antidepressant-like effects.
• ▪VCU-1012 administration reduced anxiety in mice with chemotherapy-induced mood disturbances.

Brain plasticity mechanisms

• ▪The novel compound VCU-1012 promoted structural plasticity in mice by increasing the density of dendritic spines in the frontal cortex.
• ▪To visualize structural plasticity, researchers used a herpes simplex virus to deliver a fluorescent protein into the mouse frontal cortex, making brain cells glow green under a microscope.

Receptor selectivity engineering

• ▪Computer modeling and genetic tests showed that VCU-1012 binds to the orthosteric binding pocket of the serotonin 2A receptor differently from conventional drugs, enabling precise activation of healing pathways.
• ▪The original compound quipazine has an unusual chemical structure containing three basic nitrogen atoms, whereas most psychedelics contain only one.
• ▪To engineer VCU-1012, researchers systematically deconstructed quipazine around a quinazoline core to isolate therapeutic features from those causing stomach discomfort.

Gastrointestinal side effect reduction

• ▪Unlike its parent compound quipazine, VCU-1012 did not slow digestion when tested in mice, indicating a reduction in off-target gastrointestinal side effects.
• ▪VCU-1012 demonstrated selective activation of the serotonin 2A receptor in engineered human cells while avoiding the serotonin 3A gut receptor that causes nausea.

3 sources